Inhibition of the Growth of Patient-Derived Pancreatic Cancer Xenografts with the MEK Inhibitor Trametinib Is Augmented by Combined Treatment with the Epidermal Growth Factor Receptor/HER2 Inhibitor Lapatinib

Mutations of the oncogene KRAS are important drivers of pancreatic cancer progression. Activation of epidermal growth factor receptor (EGFR) and human EGFR2 (HER2) is observed frequent in pancreatic adenocarcinomas. Because of co-activation of these two signaling pathways, we assessed the efficacy o...

Full description

Saved in:
Bibliographic Details
Main Authors: Walters, Dustin M, Lindberg, James M, Adair, Sara J, Newhook, Timothy E, Cowan, Catharine R, Stokes, Jayme B, Borgman, Cheryl A, Stelow, Edward B, Lowrey, Bryce T, Chopivsky, Maria E, Gilmer, Tona M, Parsons, John T, Bauer, Todd W
Format: Artigo
Language:Inglês
Published: Neoplasia Press Inc. 2013
Subjects:
Research Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3579317/
https://ncbi.nlm.nih.gov/pubmed/23441129
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items